

Jarushka Naidoo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4057376/jarushka-naidoo-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

100
papers

7,394
citations

41
h-index

85
g-index

111
ext. papers

10,875
ext. citations

7.3
avg, IF

5.76
L-index

#	Paper	IF	Citations
100	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020 , 395, 1907-1918	41.1	18880
99	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 1976-1986	59.2	865
98	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 709-717	2.2	587
97	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017 , 7, 264-276	24.4	491
96	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019 , 570, 385-389	50.4	339
95	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 43-50	2.4	248
94	Management of Immunotherapy-Related Toxicities, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 255-289	7.3	246
93	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. <i>Clinical Cancer Research</i> , 2016 , 22, 3618-3629	12.9	242
92	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016 , 4, 383-9	12.5	199
91	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019 , 115, 854-868	9.9	167
90	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 916-925	4	162
89	Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1930-1939	8.9	160
88	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. <i>Cancer</i> , 2015 , 121, 3212-3220	6.4	119
87	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 860-867	8.9	118
86	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019 , 79, 1214-1225	10.1	117
85	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 230-241	7.3	112
84	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. <i>Chest</i> , 2018 , 154, 1416-1423	5.3	111

83	Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. <i>Cancer Immunology Research</i> , 2014 , 2, 127-32	12.5	104
82	Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 553-557	5.3	89
81	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. <i>Clinical Lung Cancer</i> , 2016 , 17, e121-e129	4.9	83
80	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2738-2745	2.2	82
79	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 332-338	2.4	81
78	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020 , 6, 1952-1956	13.4	79
77	2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors. <i>Journal of Clinical and Translational Science</i> , 2018 , 2, 44-45	0.4	78
76	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020 , 38, 576-583	2.2	71
75	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. <i>Nature Cancer</i> , 2020 , 1, 99-111	15.4	67
74	Immune-Related Adverse Events From Immune Checkpoint Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 100, 242-51	6.1	66
73	Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 494-502	8.9	64
72	The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. <i>Cancer Immunology Research</i> , 2018 , 6, 888-899	12.5	60
71	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events 2021 , 9,		58
70	Immune checkpoint blockade. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 585-600	3.1	57
69	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101440	2.2	55
68	Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019 , 79, 1204-1213	10.1	50
67	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <i>Oncologist</i> , 2017 , 22, 627-630	5.7	49
66	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, e31-e43	10.2	48

65	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4305-4315	15.9	47
64	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1327-1337	12.9	46
63	A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 712-720	7.3	44
62	Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019 , 20, e470-e479	4.9	42
61	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101308	2.2	42
60	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer 2020 , 8,		40
59	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , 2021 , 596, 126-132	50.4	40
58	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. <i>PLoS ONE</i> , 2017 , 12, e0182665	3.7	35
57	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology, The</i> , 2020 , 21, e398-e404	21.7	35
56	Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series 2018 , 6, 104		35
55	Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 537-44	8.9	28
54	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 2019 , 7, 40		28
53	Should patients with extrapulmonary small-cell carcinoma receive prophylactic cranial irradiation?. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1215-21	8.9	26
52	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1030-1041	8.9	26
51	Immune-Related Adverse Events: A Case-Based Approach. <i>Frontiers in Oncology</i> , 2019 , 9, 530	5.3	22
50	Emerging immunotherapy strategies in breast cancer. <i>Immunotherapy</i> , 2014 , 6, 195-209	3.8	22
49	Pneumonitis From Anti-PD-1/ PD-L1 Therapy. <i>Oncology</i> , 2017 , 31, 739-46, 754	1.8	22
48	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, e435-e444 ^{4.9}	4.9	21

47	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors 2021 , 9,		20
46	KRAS-Mutant Lung Cancers in the Era of Targeted Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 893, 155-178	3.6	18
45	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <i>Journal of Oncology Practice</i> , 2019 , 15, e825-e834	3.1	18
44	Immune-related adverse events and the balancing act of immunotherapy.. <i>Nature Communications</i> , 2022 , 13, 392	17.4	18
43	Chronic immune checkpoint inhibitor pneumonitis 2020 , 8,		17
42	Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. <i>PLoS ONE</i> , 2016 , 11, e0146063	3.7	15
41	Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. <i>Cancer</i> , 2015 , 121, 2078-82	6.4	12
40	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management 2020 , 8,		12
39	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3978-3992	2.2	12
38	Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes 2021 , 9,		12
37	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016 , 102, 21-27	5.9	10
36	Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. <i>Current Oncology Reports</i> , 2020 , 22, 56	6.3	9
35	Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 46	5.4	9
34	Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, e169-e170	4.9	9
33	Principles of Immunotherapy in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020 , 30, 187-198	3.1	8
32	What does the future hold for immunotherapy in cancer?. <i>Annals of Translational Medicine</i> , 2016 , 4, 177	3.2	8
31	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016 , 37, 771-782	3.9	8
30	Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 467-472	7.3	8

29	Frequency, impact and a preclinical study of novel gene family mutations in HER2-positive breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918778297	5.4	7
28	A multidisciplinary toxicity team for cancer immunotherapy-related adverse events.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6538-6538	2.2	6
27	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers 2021 , 9,		6
26	The next frontier in non-small cell lung cancer: synergizing radiation therapy and immune checkpoint blockade. <i>Clinical Advances in Hematology and Oncology</i> , 2017 , 15, 615-625	0.6	6
25	Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma 2020 , 8,		5
24	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2021 , 27, 2571-2583	12.9	5
23	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100074	1.4	4
22	Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies. <i>Oncologist</i> , 2021 , 26, e1822-e1832	5.7	4
21	Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.. <i>Cancer Treatment Reviews</i> , 2022 , 106, 102378	14.4	4
20	Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC.. <i>Cancer Treatment Reviews</i> , 2022 , 104, 102350	14.4	2
19	Information Visualization Platform for Postmarket Surveillance Decision Support. <i>Drug Safety</i> , 2020 , 43, 905-915	5.1	2
18	Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. <i>Journal of Dermatological Treatment</i> , 2021 , 1-5	2.8	2
17	Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis. <i>Cancer Investigation</i> , 2021 , 39, 789-796	2.1	2
16	Reply to M. Nishino et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1629-1630	2.2	1
15	An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition. <i>Journal of Clinical Investigation</i> , 2019 , 129, 75-77	15.9	1
14	Successful Treatment of Scar Pain with Scrambler Therapy. <i>Cureus</i> , 2019 , 11, e5903	1.2	1
13	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. <i>Lung Cancer: Targets and Therapy</i> , 2021 , 12, 123-131	2.9	1
12	Lung cancer and family-centered concerns. <i>Supportive Care in Cancer</i> , 2020 , 28, 497-505	3.9	1

11	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.. <i>Lung Cancer</i> , 2022 , 166, 84-93	5.9	○
10	A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities. <i>Oncologist</i> , 2020 , 25, e1589-e1592	5.7	○
9	Multidisciplinary Approach to Immune-Mediated Diarrhea and Colitis From Immunotherapy for Cancer. <i>JCO Oncology Practice</i> , 2020 , 16, 462-463	2.3	○
8	Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100220	1.4	○
7	Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors.. <i>Cancer Immunology, Immunotherapy</i> , 2022 , 1	7.4	○
6	4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs. <i>Journal of Clinical and Translational Science</i> , 2020 , 4, 73-73	0.4	
5	Should patients with extrapulmonary small cell carcinoma receive prophylactic cranial irradiation? An Irish experience.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2609-2609	2.2	
4	An Irish breast cancer survivorship study: Are we meeting our patientsNeeds?. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20687-e20687	2.2	
3	Immune-Related Adverse Events and Efficacy-The More It Hurts, the Better It Works?-Reply. <i>JAMA Oncology</i> , 2021 , 7, 945	13.4	
2	Preoperative contralateral lung radiation dose is associated with postoperative pulmonary toxicity in patients with locally advanced non-small cell lung cancer treated with trimodality therapy. <i>Practical Radiation Oncology</i> , 2018 , 8, e239-e248	2.8	
1	Non-Rheumatic Immune-Related Adverse Events 2021 , 191-253		